American Civil Liberties Union

 
   TIMELINE
   HEARING TRANSCRIPTS (PDF)
Aug. 22, before the DEA
Aug. 23, before the DEA
Aug. 24, before the DEA
Aug. 25, before the DEA
Aug. 26, before the DEA
Dec. 12, before the DEA
Dec. 13, before the DEA
Dec. 14, before the DEA
Dec. 16, before the DEA
   NEWS

MAPS Founder Rick Doblin's Blog on the Hearings >> (Off site)

   LEGAL DOCUMENTS
Supreme Court Ruling on Gonzales v. Raich
1988 Ruling by DEA Administrative Law Judge Francis L. Young that Marijuana be Rescheduled (Off site)


Post-Raich protest in Santa Cruz, Calif.

TAKE ACTION!
Urge Congress to stop federal obstruction of medical marijuana research >>

WHAT LAWMAKERS SAY

Letter from 38 Members of Congress in support of Prof. Craker. (PDF)

Letter from Grover Norquist in Support of Prof. Craker. (PDF)

Dear Colleague letter from Rep. Farr (D-CA) questioning NIDA's impartiality toward marijuana research. (PDF)
Letter from MA Senators Kerry and Kennedy to DEA in support of UMASS marijuana production facility. (PDF)
WHAT SCIENTISTS SAY
Marijuana and Medicine: Assessing the Science Base - National Academy of Sciences, Institute of Medicine Report, 1999. (Off site)
Marihuana: A Signal of Misunderstanding, The Report of the National Commission on Marihuana and Drug Abuse, Commissioned by President Richard Nixon, 1972. (Off site)
Comprehensive bibliography of scientific research on marijuana. (PDF)
Letter in Support of Prof. Craker from the California Medical Association (PDF)

LATEST NEWS
Medical Marijuana Is Now One Step Away from the FDA Development Process Following a Groundbreaking Ruling by a DEA Judge >>

Read the Judge's Forceful Opinion >>
LISTEN
ACLU Attorney Allen Hopper discusses the decision

The American Civil Liberties has challenged the U.S. Drug Enforcement Administration's policy of obstructing privately funded, FDA-approved scientific research that could lead to marijuana being approved as a prescription medicine.

The ACLU's Drug Law Reform Project represents University of Massachusetts Professor Lyle Craker, Ph.D. in his appeal of the DEA's refusal to grant him a license to grow research-grade marijuana for use in studies that aim to lay the groundwork for developing medical marijuana into a legal, prescription medicine. Were medical marijuana developed through the pharmaceutical process into a legal medicine, patients would be able to safely access it in pharmacies instead of from corner drug dealers.

Professor Lyle E. Craker is appealing the DEA's denial of application to grow marijuana for medical research.

MDMA (also known as Ecstasy), LSD, heroin and cocaine are all more readily available to researchers for medicinal studies than is marijuana. Through the National Institute on Drug Abuse (NIDA), the federal government maintains a monopoly on the supply of marijuana available for research. Scientists who want to study the medical benefits of marijuana with the goal of developing it into an FDA-approved prescription medicine either cannot obtain marijuana for their research or receive from NIDA marijuana of inferior quality and insufficient potency to meet the FDA's drug approval standards.

Science, not politics, should guide medicine in America. Federal agencies such as the DEA and NIDA have been blocking research and obstructing honest efforts by researchers and scientists to find a way for patients to get the medicine they need without risking prosecution and imprisonment and without  resorting to the  black market. The time has come for the federal government and the DEA to hear the call of science and approve Professor Craker's application to grow medical marijuana for this critically needed research.

 

WHO IS INVOLVED
Lyle E. Craker, Ph.D. is a professor at the University of Massachusetts, Amherst. His research has centered on medicinal and aromatic plants. He is currently appealing the DEA's denial of his application to grow marijuana for medical research. Learn more >>

 
Allen Hopper is a senior staff attorney at the ACLU's Drug Law Reform Project. He represents Prof. Craker in his appeal of the DEA's denial of his application to grow research-grade marijuana. Learn more >>

 
Rick Doblin is the founder and director of the non-profit research and educational organization, the Multidisciplinary Association for Psychedelic Studies. Learn more >>

 

 

Your Local ACLUcongressional scorecardmultimediaforumspublicationssupport usstorecontact